How many insider trades does FilingIQ track for INDP?

FilingIQ tracks 37 Form 4 insider transactions for INDP (Indaptus Therapeutics, Inc.), covering filings from Sep 14, 2021 onwards. 3 of those were filed in the last 90 days.

Are INDP insiders net buyers or net sellers?

Across the full Form 4 history for INDP, 16 transactions (43%) were open-market purchases and 4 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does INDP insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is INDP in?

Indaptus Therapeutics, Inc. (INDP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.08M.

INDP insider trading

Healthcare

Indaptus Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

43% / 11%

Market cap

$4.08M

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Company website: indaptusrx.com

INDP insider activity at a glance

FilingIQ has scored 37 insider transactions for INDP since Sep 14, 2021. The most recent filing in our index is dated Mar 23, 2026.

Across the full history, 16 open-market purchases and 4 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on INDP insider trades is 66.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live INDP trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for INDP?: FilingIQ tracks 37 Form 4 insider transactions for INDP (Indaptus Therapeutics, Inc.), covering filings from Sep 14, 2021 onwards. 3 of those were filed in the last 90 days.
Are INDP insiders net buyers or net sellers?: Across the full Form 4 history for INDP, 16 transactions (43%) were open-market purchases and 4 (11%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does INDP insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is INDP in?: Indaptus Therapeutics, Inc. (INDP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.08M.

Methodology & sources

Every INDP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.